Dyslipidemia Management in Adults With Diabetes

Lazarte, Julieta; Hegele, Robert A.

doi:10.1016/j.jcjd.2019.07.003

Cited by 55 publications

(44 citation statements)

References 76 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, in addition to blood glucose and HbA1c levels, serum concentrations of liver biomarkers, including ALT and AST, were measured. Also, dyslipidemia is a diabetes consequence characterized by hypertriglyceridemia and elevated LDL cholesterol (Lazarte & Hegele, 2020); therefore, serum TG and total cholesterol were measured.…”

Section: Resultsmentioning

confidence: 99%

Camel milk as an alternative treatment regimen for diabetes therapy

Hussain

Wattoo

et al. 2021

Food Science & Nutrition

View full text Add to dashboard Cite

Camel milk is a valuable source of nutrition with a wide range of therapeutic effects. Its unique composition helps to regulate the blood glucose level. The current study is aimed to evaluate the antidiabetic and hepatoprotective effects, as well as lipid profile restoration of camel milk in the diabetic mouse model. This innovative study evaluates the therapeutic effects of camel milk in diabetic mice by simultaneous measurement of blood glucose, HbA1c, ALT, AST, TG, cholesterol, and histopathological studies. The results showed that camel milk has significantly reduced blood glucose, HbA1c (p < .001), aspartate transaminase (AST), alanine transaminase (ALT) (p < .01), triglyceride (TG), and cholesterol (p < .01), compared to that in the diabetic control group. Also, the therapeutic effects of camel milk were completely comparable with the antidiabetic drug glibenclamide. The results of this study suggest that camel milk could be used as a proper alternative treatment regimen for diabetes therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Camel milk as an alternative treatment regimen for diabetes therapy

Hussain

Wattoo

et al. 2021

Food Science & Nutrition

View full text Add to dashboard Cite

show abstract

“…Another is that stress also causes cardiovascular diseases as increased production of adrenalin and noradrenaline contribute to hypertension and hyper-coagulation, and that cholesterol is a precursor for cortisol and other steroid stress hormones [107]. However, whether this new view reflects what really happens at the molecular level is unclear as this study looked at the general population and not individuals with T1DM and T2DM, in which lipid-lowering drugs remain an essential treatment to prevent the development of complications, including cardiovascular diseases [104,105].…”

Section: Changes In Lipid Metabolism At the Origin Of Atherosclerosismentioning

confidence: 98%

“…Both T1DM and T2DM are associated with changes in lipid metabolism. Plasma cholesterol, low-density lipoprotein (LDL) and triglyceride concentrations are increased and high-density lipoprotein (HDL) concentration is decreased in individuals with T2DM, and in individuals with T1DM and bad glycaemic control [103,104]. Unchanged cholesterol levels in individuals with T1DM and good glycaemic control can be deceptive as lipid profiles and functioning are altered [105,106].…”

Section: Changes In Lipid Metabolism At the Origin Of Atherosclerosismentioning

confidence: 99%

Coagulatory Defects in Type-1 and Type-2 Diabetes

Sobczak

Stewart

2019

IJMS

View full text Add to dashboard Cite

Diabetes (both type-1 and type-2) affects millions of individuals worldwide. A major cause of death for individuals with diabetes is cardiovascular diseases, in part since both types of diabetes lead to physiological changes that affect haemostasis. Those changes include altered concentrations of coagulatory proteins, hyper-activation of platelets, changes in metal ion homeostasis, alterations in lipid metabolism (leading to lipotoxicity in the heart and atherosclerosis), the presence of pro-coagulatory microparticles and endothelial dysfunction. In this review, we explore the different mechanisms by which diabetes leads to an increased risk of developing coagulatory disorders and how this differs between type-1 and type-2 diabetes.

show abstract

“…In a physician survey, Wander et al highlighted that 50% doctors in India chose not to use a statin in persons with diabetes, irrespective of their LDL-C levels [23]. For individuals with diabetes having CVD, most guidelines recommend intensive statin therapy alongside lifestyle modifications, or a 10-year risk of a cardiovascular event [28]. Addition of non-statins such as ezetimibe can be beneficial for the high-risk statin-treated patients with diabetes.…”

Section: Discussionmentioning

confidence: 99%

“…Addition of non-statins such as ezetimibe can be beneficial for the high-risk statin-treated patients with diabetes. The ACCORD-lipid trial suggested that addition of fenofibrate therapy may reduce CVD events in diabetic patients with hypertriglyceridemia and low HDL-C [28][29][30]. Evidence from multiple studies have evaluated the potential effect of PCSK9 inhibitors, bile acid sequestrants, niacin, omega-3-fatty acids as add-on therapies to statins for patients with diabetes [29,30].…”

Section: Discussionmentioning

confidence: 99%

Low-Density Lipoprotein Cholesterol Levels Among Individuals Receiving Statin Therapy: Real-World Evidence from India

Borgharkar¹,

Das²

2021

AJHR

View full text Add to dashboard Cite

Despite the established clinical effectiveness of statin therapy, a substantial proportion of patients fail to attain the target low-density lipoprotein cholesterol (LDL-C) levels and remain at risk for cardiovascular events. This study aimed to evaluate the proportion of patients achieving the guideline recommended LDL-C levels in real-world settings after receiving statins for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in India. The study included a cross-sectional retrospective analysis of medical records from 2281 private healthcare facilities between 2017 and 2018. Overall, 15879 patients aged 20-80 years irrespective of their ASCVD status were included. Mean (±SD) age of patients was 55.96±10.41 years; 62.8% were men, and 44.6% (n=7076) had clinical ASCVD. Overall, 96.2% (n=15271) patients were receiving statins, 99.3% in the secondary prevention and 93.6% in the primary prevention cohort. Most patients were receiving moderate-intensity statins for primary (89.7%, n=7391) and secondary ASCVD prevention (73.4%, n=5159). None of the patients in the secondary prevention cohort achieved the recommended LDL-C level of <70 mg/dL. Approximately 25.3% (n=2089) individuals in the primary prevention and 20.2% (n=1418) in the secondary prevention cohort achieved LDL-C <100 mg/dL. Similar proportion (23.2%, n=3361) of patients with LDL-C control (<100 mg/dL) were found among the high-risk coronary heart disease (CHD) or CHD-equivalent group (including those with diabetes). This large real-world study demonstrated levels of LDL-C that were higher than guideline recommended targets, especially among ASCVD patients, despite receiving statin therapy. The results highlight major gaps in the real-world practice of prescribing statin therapy for both primary and secondary prevention of ASCVD. Concordance to guideline recommended therapy, timely dose titration, use of alternative drugs, and patient adherence can bridge this gap and help achieve optimal control of LDL-C. Further intensification of therapy with addition of non-statins is recommended if LDL-C goals are not achieved among high-risk population.

show abstract

Dyslipidemia Management in Adults With Diabetes

Cited by 55 publications

References 76 publications

Camel milk as an alternative treatment regimen for diabetes therapy

Camel milk as an alternative treatment regimen for diabetes therapy

Coagulatory Defects in Type-1 and Type-2 Diabetes

Low-Density Lipoprotein Cholesterol Levels Among Individuals Receiving Statin Therapy: Real-World Evidence from India

Contact Info

Product

Resources

About